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nel through theNa channel’s supposed calcium sensitivity.
While there are proponents for both sides, there has been
relatively little research that provides strong evidence for
either case. In this experiment, the effect of calmodulin on
NaV 1.5 is tested by preparing a set of cardiac cells (of the
human specie) with the NaV 1.5 C-Termini and CaM pro-
tein, whichwere then to be placed in solutionswith varying
concentrations of calcium.We took special care to test mul-
tiple concentrations of calcium, as previous studies have
tested very low concentrations, with Manu Ben-Johny’s
team from the JohnHopkins laboratory in particular testing
up to a meager 50 micromolar, despite producing a well-
respected paper (By comparison, the average Na channel
can naturally sustain a concentration of almost 1-2millimo-
lar and on someoccasions, reaching evenhigher concentra-
tions). After using light scattering and observing the signals
given off by the calcium interactingwith theseNav1.5/CaM
complexes across the varying calcium concentrations, the
overall pattern indicated that there was a one to one stoi-
chiometry between calmodulin and Nav 1.5. More impor-
tantly, it indicated calcium sensitivity of the Na channel.
With this research, a definitive answer has been drawn
regarding the importanceof calmodulin in calciummodula-
tion in Na channels. Not only does this have the effect of
creating a foundation for further research into the structure
and function of Na channels, but it also gives deep insight
into fundamental functions of the channel that can play a
major role into the creation of drugs to treat the many car-
diac diseases associated with dysfunction of the channel.
http://dx.doi:10.1016/j.jsha.2016.04.044
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Rapid diagnosis and management of AMI have great
impact on morbidity and mortality. Diagnosis which is
based on elevation of cardiac biomarkers has its limita-
tions. Copeptin is the C-terminal part of the vasopressin
prohormone. The pathophysiology mode of release
should theoretically add diagnostic information of car-
diac cell necrosis. One of the major limitations of cardiac
biomarkers is the delayed release in circulation. So look-
ing for a new marker with a short diagnostic time window
is needed. Aim is to determine the role of copeptin as an
early marker for acute non-ST elevation MI (NSTEMI).
This study included 88 patients with chest pain. They
were divided into 2 groups. Group (1); included 30
patients with diagnosis of NSTEMI. Diagnosis of AMI
was established according to the universal definition of
MI. Group (2); included 58 patients with diagnosis of
unstable angina (UA). Full medical history, physical
examination, 12 lead ECG, random blood glucose level,
renal function, total cholesterol, triglyceride, cardiac tro-
ponin I and Copeptin were obtained on admission. Fol-
low up cardiac troponin I was done. Inclusion criteria:
Defined as chest pain of 66 h duration since onset, sug-
gestive of myocardial ischemia, and lasting >20 min. at
rest. Exclusion criteria: Patients with positive First cardiac
troponin were rolled out, patients with ST segment eleva-
tion were rolled out. Other exclusion criteria: Patients
presenting after a cardiac arrest, Trauma or major sur-
gery within the last 4 week; pregnancy; IV drug abuse;
age less than 18 years; shock and sepsis. Patients who
were included had second troponin I re- done and copep-
tin analysis done. In group 1 (NSTEMI) 28 patients had
ECG changes and only 2 had NSTEMI without ECG
changes. In group 2 (UA) 23 patients had ECG changes
and 35 patients had normal ECG. Males and females
were 49 and 39. Age in G1 and G2 was 60 ± 4 and
53 ± 5. Copeptin analysis was done 6 h after Infarction
or chest pain. All the patients with NSTEMI (30) had
positive copeptin and positive troponin except one only
who had + troponin only and another one who had +
copeptin only. Of the 58 patients without MI none had
the two tests positive, only one had + troponin and one
had + copeptin. Using ROC curve: copeptin had sensitiv-
ity 100% and specificity 82.8% with using cut off point
13.2 pmol/l. So copeptin can be used for early detection
of myocardial infarction. Copeptin seems to be an ideal
confirmatory marker for rapid rule out of AMI. If the
two tests (with troponin) are positive, this is evident
MI; if the two are negative it rules out MI.
http://dx.doi:10.1016/j.jsha.2016.04.045
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45. Ezetimibe and statins yields on silent holter
ambulatory myocardial ischemia
W. Kadro
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Further cholestrol lowering may affect silent ischemia
detected on holter monitoring. Cholesterol lowering is
associated with a reduction in cardiovascular morbidity
and mortality. Statins are the main drugs for cholesterol
lowering. Ezetimibe when added to statins gives further
reduction in cholesterol but its long-term effect on cardi-
ovascular morbidity and mortality and ischemic events is
not known. This study sought to determine whether
further cholesterol lowering with ezitimibe will also
results in a reduction of myocardial ischemia during daily
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